Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
Type:
Grant
Filed:
May 23, 2023
Date of Patent:
February 24, 2026
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
August 11, 2023
Date of Patent:
May 27, 2025
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Type:
Grant
Filed:
December 7, 2021
Date of Patent:
November 26, 2024
Assignee:
COMPUGEN LTD.
Inventors:
Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
June 17, 2020
Date of Patent:
October 24, 2023
Assignee:
COMPUGEN LTD.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: The present invention is directed to PVRIG polypeptides and their uses.
Type:
Grant
Filed:
January 28, 2020
Date of Patent:
October 24, 2023
Assignee:
COMPUGEN LTD.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
Type:
Grant
Filed:
June 17, 2020
Date of Patent:
July 18, 2023
Assignee:
COMPUGEN LTD.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
April 11, 2023
Assignee:
COMPUGEN LTD.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.
Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
January 18, 2022
Assignee:
Compugen Ltd.
Inventors:
Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
September 27, 2016
Date of Patent:
January 11, 2022
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
Type:
Grant
Filed:
August 17, 2017
Date of Patent:
August 25, 2020
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
July 16, 2019
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
March 12, 2019
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
February 26, 2019
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
November 13, 2018
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
Type:
Application
Filed:
February 28, 2017
Publication date:
August 17, 2017
Applicant:
Compugen Ltd.
Inventors:
Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
Type:
Application
Filed:
April 30, 2016
Publication date:
August 17, 2017
Applicant:
Compugen Ltd.
Inventors:
Galit ROTMAN, Iris HECHT, Zurit LEVINE, Joseph R. PODOJIL, Stephen D. MILLER
Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
Type:
Grant
Filed:
September 27, 2016
Date of Patent:
July 25, 2017
Assignee:
Compugen Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis